| Investigating the function of Fc‐specific binding of IgM to Plasmodium falciparum erythrocyte membrane protein 1 mediating erythrocyte rosetting L Stevenson, P Huda, A Jeppesen, E Laursen, JA Rowe, A Craig, ... Cellular microbiology 17 (6), 819-831, 2015 | 69 | 2015 |
| Invisible detergents for structure determination of membrane proteins by small‐angle neutron scattering SR Midtgaard, TA Darwish, MC Pedersen, P Huda, AH Larsen, ... The FEBS journal 285 (2), 357-371, 2018 | 57 | 2018 |
| Nanobody-displaying porous silicon nanoparticles for the co-delivery of siRNA and doxorubicin T Tieu, M Wojnilowicz, P Huda, KJ Thurecht, H Thissen, NH Voelcker, ... Biomaterials Science 9 (1), 133-147, 2021 | 28 | 2021 |
| Targeting the undruggable: emerging technologies in antibody delivery against intracellular targets S Niamsuphap, C Fercher, S Kumble, P Huda, SM Mahler, CB Howard Expert Opinion on Drug Delivery 17 (9), 1189-1211, 2020 | 27 | 2020 |
| PET/CT Based In Vivo Evaluation of 64Cu Labelled Nanodiscs in Tumor Bearing Mice P Huda, T Binderup, MC Pedersen, SR Midtgaard, DR Elema, A Kjær, ... PLoS One 10 (7), e0129310, 2015 | 26 | 2015 |
| Understanding nanomedicine treatment in an aggressive spontaneous brain cancer model at the stage of early blood brain barrier disruption PW Janowicz, ZH Houston, J Bunt, NL Fletcher, CA Bell, G Cowin, ... Biomaterials 283, 121416, 2022 | 17 | 2022 |
| Mg2+-dependent conformational equilibria in CorA and an integrated view on transport regulation NT Johansen, M Bonaccorsi, T Bengtsen, AH Larsen, FG Tidemand, ... Elife 11, e71887, 2022 | 13 | 2022 |
| Pre-targeting of polymeric nanomaterials to balance tumour accumulation and clearance NL Fletcher, A Prior, O Choy, J Humphries, P Huda, S Ghosh, ZH Houston, ... Chemical Communications 58 (57), 7912-7915, 2022 | 10 | 2022 |
| Delivery of PEGylated liposomal doxorubicin by bispecific antibodies improves treatment in models of high-risk childhood leukemia E Moles, CB Howard, P Huda, M Karsa, H McCalmont, K Kimpton, A Duly, ... Science Translational Medicine 15 (696), eabm1262, 2023 | 7 | 2023 |
| Confined microemulsion sono-polymerization of poly (ethylene glycol) nanoparticles for targeted delivery Z Gao, X Li, K Zhao, H Geng, P Zhang, Y Ju, P Huda, CB Howard, ... Chemical Communications 58 (56), 7777-7780, 2022 | 7 | 2022 |
| Clinical development of an anti-GPC-1 antibody for the treatment of cancer S Ghosh, P Huda, N Fletcher, D Campbell, KJ Thurecht, B Walsh Expert Opinion on Biological Therapy 22 (5), 603-613, 2022 | 4 | 2022 |
| Pharmacokinetics and Biodistribution of 89Zr-Miltuximab and Its Antibody Fragments as Glypican-1 Targeting Immuno-PET Agents in Glioblastoma S Ghosh, NL Fletcher, P Huda, ZH Houston, CB Howard, ME Lund, Y Lu, ... Molecular pharmaceutics 20 (3), 1549-1563, 2023 | 3 | 2023 |
| Development of targeted micelles and polymersomes prepared from degradable RAFT-based diblock copolymers and their potential role as nanocarriers for chemotherapeutics SE Ahmed, NL Fletcher, AR Prior, P Huda, CA Bell, KJ Thurecht Polymer Chemistry 13 (27), 4004-4017, 2022 | 3 | 2022 |
| Development and validation of a targeted treatment for brain tumors using a multi-drug loaded, relapse-resistant polymeric theranostic W Chu, ZH Houston, NL Fletcher, P Huda, M Ahamed, TX Lim, BW Day, ... Biomacromolecules 24 (6), 2674-2690, 2023 | 2 | 2023 |
| Antibody-based formats to target glioblastoma: overcoming barriers to protein drug delivery S Ghosh, P Huda, NL Fletcher, CB Howard, B Walsh, D Campbell, ... Molecular Pharmaceutics 19 (5), 1233-1247, 2022 | 2 | 2022 |
| Targeted delivery of polo-like kinase 1 siRNA nanoparticles using an EGFR-PEG bispecific antibody inhibits proliferation of high-risk neuroblastoma. A Logan, CB Howard, P Huda, K Kimpton, Z Ma, KJ Thurecht, ... Journal of Controlled Release 367, 806-820, 2024 | 1 | 2024 |
| RAFT Polymer–Antibody Conjugation: Squaramide Ester Chemistry Leads to Conjugates with a Therapeutic Anti-EGFR Antibody with Full Retention of Activity and Increased Tumor … A Ardana, S Ghosh, P Huda, NL Fletcher, KJ Thurecht, CC Williams Molecular Pharmaceutics 20 (6), 3073-3087, 2023 | 1 | 2023 |
| Combined SAXS and Microfludics for time-resolved structural studies of bimolecules L Arleth, GV Jensen, P Huda, S Skou, W Shang, S Chakravarthy Acta Cryst 70, C609, 2017 | 1 | 2017 |
| Click‐on Antibody Fragments for Customisable Targeted Nanomedicines–Site‐specific Tetrazine and Azide Functionalisation through Non‐canonical Amino Acid incorporation P Huda, J Humphries, NL Fletcher, CB Howard, KJ Thurecht, CA Bell Chemistry‐Methods 4 (2), e202300036, 2024 | | 2024 |
| Immuno-PET agents for targeting glioblastoma S Ghosh, P Huda, N Fletcher, C Howard, Y Lu, D Campbell, B Walsh, ... Internal Medicine Journal 52 (Supplement 2), 24-24, 2022 | | 2022 |
